Company Information
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug candidate, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test.
![Investor Presentation](https://www.adial.com/wp-content/uploads/2022/01/AdialPharma_CorpBro_2022.png)
Adial Corporate Presentation
PDF iconInvestor Relations
Crescendo Communications, LLCDavid Waldman
5 Penn Plaza
Suite 1953
New York, NY 10001
T: 212-671-1021
ADIL@crescendo-ir.com
Adial Pharma Contact
Adial Pharmaceuticals, Inc.4870 Sadler Road, Suite 300
Glen Allen, VA 23060
T: 1-804-487-8196
info@adialpharma.com